Tommaso De Pas - Concepedia

Author

Tommaso De Pas

Also Known As

De Pas, Tommaso, M de Pas, T De Pas, T. DE PAS, T. De Pas, T. De pas, T. de Pas, TOMMASO DE PAS, Tommaso De Pas, Tommaso Martino De Pas

272

Publications

12.7K

Citations

H-Index

Concepts

All Affiliations

European Institute of Oncology University of Milan Istituti di Ricovero e Cura a Carattere Scientifico Seoul National University Hospital KU Leuven

About

Tommaso De Pas is an author at European Institute of Oncology specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	58	3.4K
2	Health Sciences	13	15	508
3	Nursing	1	1	41
4	Public Health	1	1	56
5	Social Sciences	1	1	41

Tommaso De Pas

Publications

10.1K

Citations

H-Index

Page 1

	Year	Citations
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, New England Journal of Medicine	2013	3.4K
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, New England Journal of Medicine	2014	1.4K
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa, The Lancet Oncology OncologyImmunologyBronchial NeoplasmImmune Checkpoint InhibitorImmunotherapeutics	2016	489
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Dong‐Wan Kim, Ranee Mehra, Daniel S.W. Tan, The Lancet Oncology MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology	2016	467
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) George R. Blumenschein, Egbert F. Smit, David Planchard, Annals of Oncology Non-small-cell Lung CancerMedicinePharmacologyPathologyCancer Cell Biology	2015	355
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With <i>ALK</i> -Positive Non–Small-Cell Lung Cancer Shirish M. Gadgeel, Alice T. Shaw, Ramaswamy Govindan, Journal of Clinical Oncology	2016	195
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy Paolo Andrea Zucali, Tommaso De Pas, Giovannella Palmieri, Journal of Clinical Oncology Cancer ManagementThymic Carcinoma PreviouslyImmunologyPathologyPhase Ii Study	2017	169
A 10-Year Single-Center Experience on 708 Lung Metastasectomies: The Evidence of the “International Registry of Lung Metastases” Monica Casiraghi, Tommaso De Pas, Patrick Maisonneuve, Journal of Thoracic Oncology	2011	164
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial Vanesa Gregorc, Silvia Novello, Chiara Lazzari, The Lancet Oncology Prognostic BiomarkersMedicineRandomised Phase 3PathologyCancer Genomics	2014	158
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer Johan Vansteenkiste, Jean‐Luc Canon, Filippo de Braud, Journal of Thoracic Oncology	2015	158

Page 1